Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Neovascular AMD
NCT03465709Phase 2Terminated
- Sponsor
- Apellis Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pegcetacoplan in neovascular age-related macular degeneration (NVAMD), sponsored by Apellis Pharmaceuticals. Started Feb 2018; status: terminated.
02
Drugs
pegcetacoplan
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03465709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465709.